| Medical and Health Sciences | Lifetime | 530 | NL 15 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 788 | NL 17 | 99.82 |
| Cardiology and Cardiovascular Medicine | Lifetime | 46 | NL 2 | 99.96 |
| Emergency Medicine | Lifetime | 198 | NL 2 | 98.46 |
| Internal Medicine | Lifetime | 141 | NL 6 | 96.77 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 124 | NL 7 | 99.39 |
| Econometrics and Quantitative Economics | 2021-2025 | 786 | NL 17 | 95.04 |
| Emergency Medicine | 2021-2025 | 166 | NL 2 | 90.94 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 431 | NL 9 | 88.02 |
| Acute Myocardial Infarction Research | Lifetime | 13 | NL 1 | 99.95 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 27 | NL 2 | 99.90 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 80 | NL 9 | 99.70 |
| Heart Failure Treatment and Management | Lifetime | 49 | NL 3 | 99.80 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 50 | NL 2 | 99.67 |
| Cardiac Arrest and Resuscitation | Lifetime | 113 | NL 3 | 99.54 |
| Cardiac Imaging and Diagnostics | Lifetime | 182 | NL 10 | 99.67 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 169 | NL 7 | 99.48 |
| Cardiovascular Function and Risk Factors | Lifetime | 310 | NL 13 | 99.40 |
| Mechanical Circulatory Support Devices | Lifetime | 162 | NL 3 | 99.13 |
| Coronary Interventions and Diagnostics | Lifetime | 199 | NL 15 | 99.34 |
| Cardiac Arrhythmias and Treatments | Lifetime | 282 | NL 14 | 99.19 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 611 | NL 42 | 98.55 |
| Acute Ischemic Stroke Management | Lifetime | 544 | NL 30 | 98.46 |
| Trauma and Emergency Care Studies | Lifetime | 986 | NL 27 | 95.89 |
| Potassium and Related Disorders | Lifetime | 457 | NL 22 | 92.08 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 713 | NL 31 | 88.65 |
| GDF15 and Related Biomarkers | Lifetime | 954 | NL 24 | 73.40 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 112 | NL 7 | 98.99 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 263 | NL 16 | 97.28 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 191 | NL 7 | 95.67 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 476 | NL 15 | 95.44 |
| Acute Myocardial Infarction Research | 2021-2025 | 348 | NL 14 | 95.63 |
| Heart Failure Treatment and Management | 2021-2025 | 463 | NL 15 | 94.46 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 737 | NL 34 | 93.00 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 889 | NL 28 | 83.65 |
| Pharmacology and Obesity Treatment | 2021-2025 | 406 | NL 3 | 75.06 |
| Pharmaceutical Economics and Policy | 2021-2025 | 904 | NL 41 | 71.34 |
